

January 13, 2014



Sujal Shah Appointed Chief Financial Officer of CymaBay Therapeutics

HAYWARD, CA--(Marketwired - January 13, 2014) - CymaBay Therapeutics, Inc. announced today that Sujal Shah has been appointed Chief Financial Officer. Mr. Shah served as a consultant and acting Chief Financial Officer since June 2012 and was integral in the execution of CymaBay's recent capital restructuring and financing.

"We are pleased to have Sujal join our senior management team after serving a key role at CymaBay over the past year," said Hal Van Wart, Ph.D., President and CEO of CymaBay Therapeutics. "Sujal brings extensive strategic and financing experience to our team along with a sound foundation in biomedical sciences."

Prior to joining CymaBay, Mr. Shah served as Director, Health Care Investment Banking at Citigroup from 2010 to 2012, where he was responsible for managing client relationships and executing strategic and financing transactions for clients focused in life sciences. From 2004 to 2010, Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking. Mr. Shah received his MBA from Carnegie Mellon University Tepper School of Business in 2004 and his B.S. and M.S. degrees in Biomedical Engineering from Northwestern University in 1995 and 1997, respectively.

"I am excited about the opportunity to be part of such a dedicated and talented team here at CymaBay," said Mr. Shah. "I believe the Company's pipeline holds tremendous potential and look forward to working with the team to execute on a strategy to ultimately improve the lives of patients with unmet medical needs."

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

For additional information about CymaBay visit www.cymabay.com.

Contact:

Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
investors@cymabay.com

Adam Cutler
The Trout Group, LLC
(646) 378-2936
CymaBay@troutgroup.com